Cancer Treatment Today

The publication of study GOG-111 in 1996 and the confirmatory INTERGROUP study OV10 in 1998 changed the acceptance of cisplatin-cyclophosphamide as the “gold-standard” therapy. In trial GOG-111, patients randomized to receive paclitaxel-cisplatin had a median survival of 37.5 months compared with 24.4 months for those receiving cisplatin-cyclophosphamide. Thus, cisplatin-paclitaxel became the first-line choice for women with advanced ovarian cancer. However, there were still toxicity concerns, particularly neurotoxicity. In addition, the 24-hour paclitaxel schedule was inconvenient, requiring in-patient administration for most women. TAXOL is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, TAXOL is indicated in combination with cisplatin.

After numerous phase I/II trials of carboplatin and paclitaxel combinations, three large randomized phase III trials were performed comparing cisplatin-paclitaxel with The combination of paclitaxel and carboplatin in a three weeks schedule as is being done in this case has emerged as the current standard approach for the adjuvant treatment of ovarian cancer and to treat metastatic disease, which is the case here. The publication of study GOG-111 in 1996 and the confirmatory INTERGROUP study OV10 in 1998 changed the acceptance of cisplatin-cyclophosphamide as the “gold-standard” therapy. In trial GOG-111, patients randomized to receive paclitaxel-cisplatin had a median survival of 37.5 months compared with 24.4 months for those receiving cisplatin-cyclophosphamide. Thus, cisplatin-paclitaxel became the first-line choice for women with advanced ovarian cancer. However, there were still toxicity concerns, particularly neurotoxicity. In addition, the 24-hour paclitaxel schedule was inconvenient, requiring in-patient administration for most women. After numerous phase I/II trials of carboplatin and paclitaxel combinations, three large randomized phase III trials were performed comparing cisplatin-paclitaxel with carboplatin-paclitaxel. All three trials demonstrated equivalence with respect to median progression-free and overall survival for carboplatin-paclitaxel and cisplatin-paclitaxel. survival. As anticipated, carboplatin-paclitaxel was better tolerated and more convenient, and has since replaced the cisplatin-paclitaxel combination as the preferred regimen for first-line therapy. The combinaton of IV paclitaxel and carboplatin is now standard of care nccn.org, ovarian cancer du Bois, A, Lueck, HJ, Meier W, et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologishe Onkologie (AGO) Study Group Trial. [Abstract 1374]. Proc ASCO 1999; 18.

nccn.org, ovarian cancer

du Bois, A, Lueck, HJ, Meier W, et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologishe Onkologie (AGO) Study Group Trial. [Abstract 1374]. Proc ASCO 1999; 18.